Obalon Therapeutics

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. The company was founded in December 2002 and is headquartered in San Clemente, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in Irvine, CA.

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates

OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know

Solidified leadership and strengthened financial position in place to leverage the Company’s safe and effective weight loss system in the retail medicine setting Solidified leadership and strengthened financial position in place to leverage the Company’s safe and effective weight loss system in the retail medicine setting

Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

SAN DIEGO, Oct.  22, 2019  (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California.

Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

Shares of Obalon Therapeutics Inc (NASDAQ: OBLN), a developer of novel technologies for weight loss, were advancing strongly Thursday morning.

Obalon Shares Inflate As Weight Loss Balloon Maker Delivers Positive News

Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA.

Obalon Engages Helmuth T. Billy, MD as Medical Director for its First Company-Owned Weight Loss Treatment Center

Obalon Therapeutics Inc (OBLN) Q2 2019 Results - Earnings Call Transcript

OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 7.41% and -78.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

OBALON THERPTCS (OBLN) Reports Q2 Loss, Misses Revenue Estimates

Shares of micro-cap Obalon Therapeutics Inc (NASDAQ: OBLN) traded higher Tuesday after the company announced it has obtained two new U.S.

Obalon Wins 2 US Patents For Intragastric Balloon System

Shares of micro-cap Obalon Therapeutics (traded higher after traders circulated the U.S. patent and trademark office abstract for its Intragastric device.

Obalon Ticks Higher Amid Patent Abstract For Intragastric Device

Obalon Therapeutics Inc (NASDAQ: OBLN) shares have continued to be volatile — and that's no surprise, given that most low-float, low-volume stocks are susceptible to trader manipulation.

Obalon Clinches First US Patent For Obesity Treatment Placement System

Obalon Therapeutics Inc. shares rose 60 percent Wednesday morning, triggered by a Seeking Alpha post that said Johnson & Johnson could be making a bid for the company for $8 per share.

Obalon Closes Above $1 Following Questionable Takeover Rumor

In the latest trading session, OBALON THERPTCS (OBLN) closed at $0.68, marking a -0.37% move from the previous day.

OBALON THERPTCS (OBLN) Stock Sinks As Market Gains: What You Should Know

Medical technology company Obalon Therapeutics Inc. announced Thursday that it has entered into definitive agreements with investors for the purchase and sale of 5 million shares of common stock valued at $3 million.

Obalon Management Takes Advantage Of 200% Rally, Announces $3M Offering

OBALON THERPTCS (OBLN) closed the most recent trading day at $0.42, moving -1.96% from the previous trading session.

News for Obalon Therapeutics Stock (OBLN)